Gregory Sullivan is a Psychiatry physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1407 Williams Rd
York, PA 174029000
Telephone
717-851-6340Provider last certified this registry record 19 Dec 2025.
Clinical trials
- Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
Sponsor: Tonix Pharmaceuticals, Inc.
- Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
Sponsor: Tonix Pharmaceuticals, Inc.
- A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
Sponsor: Tonix Pharmaceuticals, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
96.6%Benzodiazepine18.8%Lorazepam38%Clonazepam30%Alprazolam21%Oxazepam5%Alprazolam Er5%Part D<11 patientsSSRI15.1%Trazodone Hcl29%Fluoxetine Hcl22%Citalopram Hbr16%Sertraline Hcl15%Paroxetine Hcl12%Escitalopram Oxalate6%Part D<11 patients+ 14 more classes in this area
Cardiovascular
3.4%alpha-Adrenergic Blocker1.3%Prazosin Hcl100%Part D<11 patientsBeta blocker1.1%Propranolol Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”